Program
enarodustat
Also written as “JTZ-951”, “Enarodustat 2mg” and “Enarodustat 3mg”.
Its studies are mostly in Anemia · Kidney Failure, Chronic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shionogi | 40 open or running | phase 1since Oct 15, 2013 | Oct 15, 2013 | none ahead |
| JW Pharmaceutical | 10 open or running | phase 3since Jul 10, 2019 | Jul 10, 2019 | none ahead |
| Shenzhen Salubris Pharmaceuticals | 11 open or running | phase 4since Jul 6, 2025 | Jul 6, 2025 | Jun 2027phase 4 · NCT07079579 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 15, 2013First study: phase 1 study in AnemiaNew to ShionogiShionogi · NCT01971164 · 29 enrolled · United States
- Nov 1, 2013Phase 1 study in Kidney Failure, ChronicShionogi · NCT01978587 · 6 enrolled · United States
- Oct 19, 2015Phase 1 study in Anemia of Chronic Kidney DiseaseShionogi · NCT02581124 · 10 enrolled · United States
- Jun 15, 2016Phase 1 study in Anemia of Chronic Kidney DiseaseShionogi · NCT02805244 · 6 enrolled · United States
- Jul 10, 2019JW Pharmaceutical's first study: phase 3 study in Anemia of Chronic Kidney DiseaseNew to JW PharmaceuticalJW Pharmaceutical · NCT04027517 · 172 enrolled · Korea, Republic of
- Jul 6, 2025Shenzhen Salubris Pharmaceuticals's first study: phase 4 study in Renal Anemia in Non-dialysis Chronic Kidney DiseaseNew to Shenzhen Salubris PharmaceuticalsShenzhen Salubris Pharmaceuticals · NCT07079579 · 120 planned · China
Ahead
- Jun 2027Primary completion: phase 4 study in Renal Anemia in Non-dialysis Chronic Kidney DiseaseShenzhen Salubris Pharmaceuticals · NCT07079579
TargetBeta
“Egl nine homolog 1 inhibitor”ChEMBL 37, by rule
Other programs on EGLN1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 47 |
| vadadustatrule | Akebia Therapeutics | phase 3 | 36 |
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07079579Renal Anemia in Non-dialysis Chronic Kidney Disease · China | 4 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals | Jun 2027 | 120 |
| NCT04027517Anemia of Chronic Kidney Disease · Korea, Republic of | 3 | Completed | JW Pharmaceutical | Feb 23, 2021 | 172 |
| NCT02805244Anemia of Chronic Kidney Disease · United States | 1 | Completed | Shionogi | Sep 2016 | 6 |
| NCT02581124Anemia of Chronic Kidney Disease · United States | 1 | Completed | Shionogi | Apr 2016 | 10 |
| NCT01978587Kidney Failure, Chronic · United States | 1 | Completed | Shionogi | Dec 2013 | 6 |
| NCT01971164Anemia · United States | 1 | Completed | Shionogi | May 2014 | 29 |
How it is read
Names in the registry
- “JTZ-951”, 4 entries
- “Enarodustat 2mg”, 1 entry
- “Enarodustat 3mg”, 1 entry
- “Enarodustat 4mg”, 1 entry
- “JTZ-951, 14C-JTZ-951”, 1 entry
Conditions, from the studies’ own filings
- Anemia, 5 studies
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.